World's Largest Resource for Cardiovascular Perfusion

Perfusion StaffingPerfusion Staffing
   +1 888-499-5672Login
Perfusion NewswireBlood ManagementTolerability of Different Oral Iron Supplements: A Systematic Review

Tolerability of Different Oral Iron Supplements: A Systematic Review

Blood Management, Main Zone, Mobile Zone, Perfusion Zone

Objective: A systematic review was conducted to analyse the tolerability of several oral iron supplements based on data obtained in available publications and to report the incidence of adverse effects (AE) for each supplement both overall and gastrointestinal. 


Methods: Electronic databases as Medline, the Cochrane Library, and Embase were searched for studies published up to January 2009. Clinical or observational studies reporting data on the tolerability of oral iron supplements were included. Results were described statistically and a quasi-binomial logistic regression model was developed to evaluate and compare the tolerability of the supplements studied. 

Results: For this review 111 studies were included, with data on 10,695 patients. Ferrous sulphate with mucoproteose had the lowest incidence of AE (4.1% for overall AE, 3.7% for gastrointestinal AE [GAE]) and was used as the reference supplement in the regression model. Incidence rates of overall AEs for the other supplements were 7.3% for iron protein succinylate [GAE: 7%; OR for AE compared to the reference supplement, 1.96], 23.5% for ferrous glycine sulphate [GAE: 18.5%; OR: 5.90], 30.9% for ferrous gluconate [GAE: 29.9%; OR: 11.06], 32.3% for ferrous sulphate without mucoproteose [GAE: 30.2%; OR: 11.21], and 47.0% for ferrous fumarate [GAE: 43.4%; OR: 19.87]. The differences in incidence of AE between extended-release ferrous sulphate with mucoproteose and all other supplements except iron protein succinylate were statistically significant at p<0.001. These findings are subject to some limitations as the designs and methodologies of the studies included show heterogeneity among them that it has partially been counteracted by the large sample size provided by the substantial number of trials, what is considered a strength in tolerability studies. 

Conclusion: Extended-release ferrous sulphate with mucoproteose appears to be the best tolerated of the different oral iron supplements evaluated.

Leave a Reply

You may also like
ECMO Zone, Perfusion Zone, Tiny Perfusion Letter

Insight Into ECMO, Mortality and ARDS: A Nationwide Analysis of 45,647 ECMO Runs

ARDS is a severe disease with a high mortality rate despite ECLS therapy. Although endpoints and timing of the evaluations differed from those of the CESAR and EOLIA studies and the Extracorporeal Life Support Organization (ELSO) Registry, the reported mortality in these studies was lower than in the present analysis. Further prospective analyses are necessary to evaluate outcomes in ECMO therapy at the centre volume level.

Join TodayJoin Today